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Data from several cancer types suggest that dysregulation of polycomb group complexes (PcGs) can contribute to malignant transformation, consistent with the fact that PcGs regulate thousands of transcripts responsible for cell fate [1] [2] [3] . The role of PcG-mediated gene silencing in cancer is supported by the observation that many cancers harbor higher levels of or activating mutations in genes encoding PcG subunits. Moreover, PcG-repressed genes include tumor suppressors such as the cyclin-dependent kinase inhibitor 2A (CDKN2a; also known as INK4a/ARF) locus [4] [5] [6] .
EZH2 is the catalytic component of polycomb repressive complex group 2 (PRC2) and was first identified in Drosophila for its role in development and differentiation. EZH2 is highly expressed in different types of B cell tumors 7, 8 and, along with the PcG proteins embryonic ectoderm development (EED) and BMI1 polycomb ring finger oncogene (BMI1), it is critical for B cell development [9] [10] [11] . Sequencing studies identified frequent mutations in the region encoding the catalytic EZH2 SET domain (for example, mutations altering Tyr646 in humans (Tyr641 in mice)) in germinal center (GC) diffuse large B cell lymphoma (DLBCL) and follicular lymphoma [12] [13] [14] . Somatic EZH2 mutations or amplifications also occur in other tumor types, including non-small-cell lung cancer, prostate cancer, colon carcinoma and melanoma [15] [16] [17] , whereas loss-of-function events appear in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) 18 and T cell acute lymphoblastic leukemia (T-ALL) 19 . These findings suggest that EZH2 may be a potential therapeutic target for cancers other than lymphoma, and there are currently five open clinical trials testing three different EZH2 inhibitors (produced by GlaxoSmithKline, Epizyme and Constellation Pharmaceuticals).
No mouse model of the most common EZH2 SET-domain-encoding mutation is currently available to investigate its cell-dependent in vivo effect or to test the efficacy of EZH2-targeted therapeutics. To understand the role and function of this mutation in malignant progression, we generated a mouse model in which the mutated Ezh2 allele is 'knocked-in' to the native locus with intact cis-regulatory elements, permitting conditional expression of the mutant protein.
We examined the ability of this allele to promote lymphoid and solid (such as melanoma) malignancies by itself and in cooperation with other oncogenic events by crossing mice with the knocked-in Ezh2 allele to mouse strains expressing tissue-specific Cre recombinase.
RESULTS

Expression of Ezh2 Y641F promotes lymphoma
We validated expression of the Ezh2 Y641F allele by Southern blot, PCR and qRT-PCR ( Fig. 1a and Supplementary Fig. 1a-d) . In the absence of Cre-mediated recombination, the allele produced a wild-type (WT) transcript (Fig. 1a) , and after Cre-mediated deletion of a loxP-flanked ('floxed') 'mini-gene' , it expressed the Ezh2 Y641F allele, which is equivalent to the most common EZH2 missense allele (EZH2 Y646F ) in human cancers 15, 17 . To assess functionality in vivo, we crossed mice with the Ezh2 Y641F allele to CD19 Cre/+ mice which constitutively express Cre recombinase in B lymphocytes 20 . CD19 + B cells from 8-week-old CD19 Cre/+ and CD19 Cre/+ Ezh2 Y641F/+ mice expressed Ezh2 transcripts at equal levels (Supplementary Fig. 1e ). Consistent with a reported gain of function of the protein encoded by the EZH2 Y641F allele in humans 21 , B cells from 8-week-old CD19 Cre/+ Ezh2 Y641F/+ mice had an approximately threefold increase in H3K27me3 amounts, as compared to those in B cells from CD19 Cre/+ Ezh2 +/+ mice and CD19 − cells (Fig. 1b) . Expression of Ezh2 Y641F had minimal effect on B cell development in 8-week-old mice (Supplementary Fig. 2a-h) .
To examine the effects of Ezh2 Y641F on B cell malignancy, we observed a cohort of littermate CD19 Cre/+ Ezh2 Y641F/+ and CD19 Cre/+ Ezh2 +/+ mice over time. In contrast to results from mice expressing Ezh2 Y641F under the control of a collagen promoter 22 , expression of Ezh2 Y641F from the endogenous locus induced highly penetrant B cell lymphoma with a median survival of 1 year ( Fig. 1c) . All of the tumors from CD19 Cre/+ Ezh2 Y641F/+ mice that were analyzed (n = 15) showed recombination of the Ezh2 allele (data not shown) and a CD45 + B220 + CD19 + IgM + CD43 + CD5 + immunophenotype; they also expressed the myeloid marker Mac1 (Supplementary Fig. 3a) . Tumor-bearing mice also showed disruption of the splenic architecture and expansion of abnormal, large lymphoid cells in the white pulp, and ~50% of the animals had frank leukemia and/or hepatic involvement ( Supplementary Fig. 3b ). The tumors showed increased expression of H3K27me3 and were readily transplantable into syngeneic recipients ( Fig. 1d and Supplementary Fig. 3c-e ). Therefore, physiological expression of Ezh2 Y641F in young mice does not markedly perturb the development of B lymphocytes, but it does seem to facilitate malignant transformation.
To determine whether genetic alterations detected in human B cell lymphomas cooperate with Ezh2 Y641F in tumor formation, we transduced hematopoietic progenitors from CD19 Cre/+ Ezh2 +/+ or CD19 Cre/+ Ezh2 Y641F/+ mice with retroviruses expressing Bcl2 or Myc. Expression of Myc subtly increased B cell lymphocytosis in CD19 Cre/+ Ezh2 Y641F/+ mice ( Supplementary Fig. 4a ), but it did not accelerate tumor formation ( Fig. 1e) . Consistent with a previous report 22 , recipients of Bcl2-transduced CD19 Cre/+ Ezh2 Y641F/+ hematopoietic progenitors developed advanced B cell lymphoma much faster than recipients of Bcl2-transduced CD19 Cre/+ Ezh2 +/+ cells (P < 0.001; Fig. 1e and Supplementary Fig. 4b,c) . Moreover, the combination of somatic Trp53 inactivation with Ezh2 Y641F expression accelerated lymphoma formation (P < 0.001; Fig. 1f and Supplementary  Fig. 4d,e ). These results suggest that globally increased H3K27me3 levels cooperate with apoptotic resistance mediated by Bcl2 overexpression or Trp53 loss to accelerate B cell transformation, consistent with the co-occurrence of these genetic alterations in human B cell lymphoma 23 . npg In vitro, EZH2 Y641F -expressing cells exhibit decreased H3K27 mono-methylase activity but increased di-and trimethylase activity, as compared to those in EZH2 +/+ cells 21, 24 , suggesting that transformation may require expression of both WT and mutant proteins. Consistent with this model, to our knowledge, all human cancers observed to date that harbor EZH2 Y641F mutations also retain a WT copy of EZH2 (refs. 13, 15, 17, 23) . To test the requirement of WT Ezh2 for tumorigenesis, we determined the tumor latency of CD19 Cre/+ Ezh2 Y641F/Y641F mice. CD19 Cre/+ Ezh2 Y641F/Y641F mice developed splenomegaly and lymphadenopathy with an infiltration of abnormal B220 low Mac1 low B cells ( Fig. 1g,h ) with kinetics and a tumor immunophenotype nearly identical to those of CD19 Cre/+ Ezh2 Y641F/+ mice. Mice heterozygous or homozygous for the Ezh2 Y641F mutation had elevated levels of H3K27me3, as compared to those in controls ( Fig. 1i) . Because both alleles from tumors of Ezh2 Y641F/Y641F underwent recombination ( Supplementary Fig. 4f ), and therefore express only mutant Ezh2, these data demonstrate that WT Ezh2 function is dispensable for tumorigenesis in cells harboring Ezh2 Y641F mutations. This observation could reflect residual monomethylase activity by the Ezh2 Y641F variant, which may not be a feature of other Tyr646 mutants of EZH2 (ref. 21); it is also possible that another H3K27 monomethylase (such as EZH1) compensates for loss of EZH2 activity in these tumors.
Ezh2 Y641F cooperates with Braf but not Nras to induce melanoma In addition to lymphoma, EZH2 Y646 mutations are observed in 3% of human melanoma [25] [26] [27] , with focal amplifications of EZH2 being noted in 15 of 262 (5.7%) cases from The Cancer Genome Atlas (TCGA). Because BRAF V600E or NRAS Q61R mutations occur in the majority of human melanomas, we tested the ability of the Ezh2 Y641F allele to cooperate with the conditionally activatable mouse alleles of Braf V600E (ref. 28) or Nras Q61R (ref. 29) in the presence of the tamoxifen-inducible tyrosinase-Cre allele (Tyr-Cre ERT2 ) 30, 31 . Melanoma was not observed in Tyr-Cre ERT2 Braf V600 mice, as previously described 29, 32 . The inclusion, however, of a heterozygous Ezh2 Y641F mutation rapidly accelerated tumorigenesis of unpigmented, nonmetastatic melanoma in the context of Braf V600E activation alone or Braf V600E in combination with a heterozygous conditional allele of phosphatase and tensin homolog ( Pten L/+ ) ( Fig. 2a-c) . Ezh2 Y641F , therefore, cooperates with mutant Braf (±haploinsufficiency of Pten) in melanoma formation and maintenance.
In contrast, melanocyte-specific activation of Ezh2 Y641F in the presence of Nras Q61R did not accelerate melanomagenesis, with or without loss of the Ink4a-encoding Cdkn2a sequence (hereafter referred to as p16 Ink4a ) ( Fig. 2d) . Because Braf is considered to be a downstream effector of Nras signaling and an upstream effector of the mitogenactivated protein kinase (MAPK) pathway (involving the MEK and ERK kinases), the differing abilities of Nras Q61R and Braf V600E to promote melanoma in the context of Ezh2 Y641F were unexpected. We carefully examined data from prior melanoma sequencing studies [25] [26] [27] using cBIOPORTAL 15, 17 . In accordance with our mouse genetic results, EZH2 mutations in human melanoma co-occur with activating mutations in BRAF at a significant frequency (P = 0.006) and are mutually exclusive with NRAS mutations (P = 0.004) ( Supplementary  Fig. 5 ). These results suggest that although RAF-MEK-ERK activation synergizes with EZH2 Y646F mutations in melanoma formation, a RAF-independent aspect of mutant RAS signaling renders the oncogenic effects of mutant EZH2 irrelevant to transformation.
We performed experiments to address the cooperation of the EZH2 mutation with BRAF but not NRAS. In the mouse, we observed that npg expression of Nras and Braf was not altered in the presence of the Ezh2 Y641F mutation (data not shown). A major pathway activated by NRAS but not BRAF is the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-protein kinase B (AKT) pathway. To determine whether mutant NRAS but not BRAF inhibits the expression or enzymatic activity of EZH2, we transduced primary human melanocytes with constructs expressing BRAF V600E , NRAS Q61K or PIK3CA CAAX , which encodes a membrane-bound and constitutively active catalytic subunit of PI3K. As previously reported 33 , expression of each resulted in oncogene-induced cellular senescence, as characterized by increased expression of p16 INK4a (Fig. 2e) , ceased cellular proliferation and flat, enlarged cellular morphology (data not shown). Expression of BRAF V600E , NRAS Q61K or PIK3CA CAAX did not significantly alter EZH2 mRNA levels (Fig. 2f) ; however, NRAS Q61K and PIK3CA CAAX , but not BRAF V600E , expression resulted in a global decrease in H3K27me3 levels (Fig. 2g) . This result is consistent with prior reports suggesting that activated AKT induces genome-wide changes in H3K27me3 (ref. 34 ) via phosphorylation and suppression of EZH2 activity 35 . These experiments suggest that Ras-PI3K activation attenuates the oncogenic effects of Ezh2 Y641F , explaining the inability of Nras Q61K to accelerate melanoma formation.
Ezh2 activity is required for tumor maintenance Next we investigated whether Ezh2 inhibition could suppress tumor growth in these mice. Short hairpin RNA (shRNA)-mediated knockdown of Ezh2 in cell lines derived from the mouse melanomas described above resulted in significant growth inhibition (P < 0.01; Fig. 3a,b ),
suggesting that Ezh2 is required not only for tumor initiation but also maintenance. To determine the importance of Ezh2 enzymatic activity, we supplemented these genetic results with a pharmacological approach. We treated cell lines derived from Tyr-Cre ERT2 Braf V600 Ezh2 Y641F/+ melanoma with three EZH2 inhibitors: UNC1999 (ref. 36 ), GSK126 (ref. 37 ) and a previously unpublished S-5′adenosyl-lmethionine (SAM)-competitive pyridinone inhibitor, JQEZ5. The inhibitors from Constellation Pharmaceuticals and Epizyme were not available to us for comparative analysis at the times of these studies. JQEZ5 was designed as an open-source compound with high potency and bioavailability, is ~10-fold selective for EZH2 over EZH1 and shows in vitro activity for the EZH2 Y646F mutant in a homogenous assay ( Supplementary Fig. 6a,b) . In a panel of Ezh2 +/+ or Ezh2 Y641F melanoma cell lines, treatment with UNC1999 or GSK126 showed halfmaximal inhibitory concentrations (EC 50 values) of >3.5 µM, regardless of Ezh2 genotype (ratio of average EC 50 (Ezh2 WT )/EC 50 (Ezh2 Y641F ) = 1.4 for both agents; Supplementary Fig. 6c ). In contrast, JQEZ5 was nearly fivefold more potent in Ezh2 Y641F -expressing melanoma cell lines than in Ezh2 WT -expressing cell lines (EC 50 (Ezh2 Y641F ) = 860 nM versus EC 50 (Ezh2 WT ) = 4.0 µM; Supplementary Fig. 6c,d) .
Treatment with all three compounds resulted in decreased H3K27me3 levels, with JQEZ5 being effective at nanomolar concentrations (Fig. 3c,d and Supplementary Fig. 7a,b ). All three compounds induced cell cycle arrest within 3-5 d of treatment at their respective EC 50 values (Fig. 3e) . Submicromolar exposures of JQEZ5 for >1 week also induced cell death in the Ezh2 Y641F lines ( Supplementary  Fig. 7c,d) . To determine whether Ezh1, an Ezh2 homolog, was npg responsible for the residual H3K27me3 signal observed after Ezh2 inhibition (Fig. 3c,d) , we knocked down Ezh1 in mutant melanoma cell lines treated with JQEZ5. Ezh1 knockdown did not affect cell growth or global H3K27me3 levels in inhibitor-treated Ezh2 +/+ or Ezh2 Y641F cell lines (Supplementary Fig. 8 ), suggesting that Ezh1 does not compensate for Ezh2 inhibition in these melanomas. We next assessed the antitumor efficacy of EZH2 inhibitors in vivo. We studied lymphoma in CD19 Cre/+ Ezh2 Y641F/+ mice with autochthonous tumors and melanoma in immunodeficient mice transplanted with cell lines derived from the tumors of Tyr-Cre ERT2 Braf V600E Pten L/+ Ezh2 Y641F/+ or Tyr-Cre ERT2 Braf V600E Pten L/L mice. After the tumors reached 10 mm 3 in size, the mice were treated with vehicle, the BRAF inhibitor dabrafenib (25 mg per kg body weight (mg/kg) daily), JQEZ5 (50 mg/kg, daily) or a combination of both. JQEZ5 was selected for these studies because it was the most efficacious compound in vitro, exhibited low toxicity and had favorable pharmacokinetic properties in vivo, comparable to those of Ezh2 inhibitors currently in clinical trials (Supplementary Fig. 6c-e ). As single agents, dabrafenib and JQEZ5 treatment resulted in tumor growth inhibition in both Ezh2 +/+ and Ezh2 Y641F/+ tumors, with dabrafenib being the more potent agent. Combinatorial treatment with dabrafenib and JQEZ5 resulted in additive activity in Ezh2 Y641F/+ but not Ezh2 +/+ tumors (Fig. 3f) . After developing lymphoma, as assessed by the appearance of pathological symptoms, CD19 Cre/+ Ezh2 Y641F/+ mice were treated with vehicle or 50 mg/kg JQEZ5 by daily intraperitoneal injection. Six days of treatment with JQEZ5 completely cleared the malignant population (B220 low Mac1 low ) from the spleen, without depleting normal B cells (Fig. 3g,h and Supplementary Fig. 6f) . These data show that a selective inhibitor of EZH2 has potent single-agent activity in vivo in an autochthonous model of Ezh2 Y641F -mutated B cell lymphoma and is effective in combination with a BRAF inhibitor in RAFmutant melanoma.
Effects of Ezh2 Y641F on RNA expression
To understand the molecular effects of Ezh2 activation in B cells and melanoma, we performed RNA-seq and H3K27me3 chromatin immunoprecipitation and sequencing (ChIP-seq). Because the expression of Ezh2 Y641F in young adult mice did not alter B cell development ( Supplementary Fig. 2) , for B cell analysis, we examined CD19 + cells isolated from the spleens of 8-week-old CD19 Cre/+ Ezh2 Y641F/+ and CD19 Cre/+ Ezh2 +/+ littermates. For melanoma experiments, we screened >20 cell lines derived from tumors of Tyr-Cre ERT2 Braf V600 Pten L/+ Ezh2 Y641F/+ mice and subcloned two lines that had not recombined the Ezh2 allele. After in vitro 4-hydroxy-tamoxifen treatment, these lines yielded isogenic lines that differed in only expression of the Ezh2 mutation. In B cells, 213 transcripts were upregulated and 346 were repressed by expression of Ezh2 Y641F (P < 0.01, Supplementary  Table 1 ), whereas 563 genes were upregulated and 746 were downregulated after expression of Ezh2 Y641F in melanoma cells (P < 0.01; Supplementary Table 2 ). Gene set enrichment analysis (GSEA) in both B cells and melanoma cell lines expressing Ezh2 Y641F revealed a significant concordance between genes downregulated in cells expressing Ezh2 Y641F and genes silenced by the PRC2 complex 38, 39 ( Fig. 4a and Supplementary Table 3) . In separate biological replicates, we confirmed by qRT-PCR the altered expression of eight transcripts identified by RNA-seq (Supplementary Fig. 9) .
The RNA-seq analysis yielded two unexpected results. In B cells, GSEA indicated that transcripts repressed by expression of Ezh2 Y641F were enriched for genes known to be repressed by Myc activation in other B lineage cells [40] [41] [42] (Fig. 4b, Supplementary Fig. 10a,b and Supplementary Table 3 ). Additionally, enrichment for Myc targets was also observed in Ezh2 Y641F -expressing melanoma cell lines ( Supplementary Table 3 ). To directly assess the relationship between MYC and EZH2 in B cells, we first used a B cell lymphoma line (P493-6) (ref. 43 ) with tetracycline (tet)-inducible MYC expression. After activation of MYC expression, EZH2 expression increased in a timedependent manner (Fig. 4c) , resulting in increased global H3K27me3 levels (Fig. 4d) . We next analyzed MYC ChIP data sets that were available through the Encyclopedia of DNA Elements (ENCODE) consortium and looked for enrichment of MYC and MYC-associated factor X (MAX; a dimerization partner of MYC) at the EZH2 locus. Our analysis showed multiple MYC-MAX binding sites at the EZH2 transcription start site (TSS), in the EZH2 promoter and at an enhancer ~50 kb 5′ to the TSS in multiple cell types, including lymphoma (Supplementary Fig. 10c) . The MYC-MAX binding peaks were associated with strong peaks of H3K27 acetylation (H3K27ac, Supplementary Fig. 10c ), suggesting transcriptional activation. These findings agree with prior studies of MYC and EZH2 expression 44, 45 and suggest that some of the oncogenic effects of MYC amplification in B cell lymphoma may be mediated by EZH2 activation.
A second unexpected finding from the RNA-seq analysis of Ezh2 Y641F cells was an increase in the expression of many genes known to be directly repressed by the PRC2 complex and EZH2such as Hoxc4, Hoxc9 and Meis1 in B cells ( Supplementary Fig. 9 and Supplementary Table 1 ) and the Hoxd gene cluster in melanoma cell lines ( Supplementary Table 2 ). By mining Epigenomics Roadmap 46 data, we noted that many of the PRC2-regulated genes that were activated by Ezh2 Y641F were densely covered with repressive H3K27me3 marks in normal B cells, suggesting that these genes are silenced in healthy cells (Supplementary Fig. 11a) . In contrast, many of the genes most strongly repressed by Ezh2 Y641F lacked H3K27me3 in normal B cells and, instead, were located near enhancer elements marked with H3K27ac (Supplementary Fig. 11b ). This suggests that Ezh2 Y641F activates certain silenced genes and silences certain activated genes.
Ezh2 Y641F expression causes global re-distribution of H3K27me3
To determine whether this apparent pattern was a direct effect of altered H3K27me3 abundance, we performed H3K27me3 ChIPseq. Principal component analysis (PCA) of the differentially expressed ChIP-seq peaks showed that the first PC of the data set reflected the Ezh2 genotype, whereas a second, weaker PC reflected the tissue of origin (B cells versus melanoma) ( Fig. 5a) . Treatment with JQEZ5 altered the peak pattern in Ezh2-mutant melanoma cell lines along the first PC toward untreated isogenic WT cells ( Fig. 5a ), suggesting that EZH2 inhibition significantly 'normalized' the peak pattern in Ezh2 Y641F -expressing cells. This hypothesis was confirmed when H3K27me3 was visualized across the entire genome (Supplementary Fig. 12a) .
We next performed hierarchical clustering of these samples by genome-wide, non-overlapping 5-kb windows that exhibited dynamic H3K27me3 marks between Ezh2 +/+ and matched Ezh2 Y641F/+ cells based on a standard deviation threshold ( Supplementary  Fig. 12b,c) . This analysis revealed two major clusters: one with increased H3K27me3 in Ezh2 +/+ samples, and a larger cluster with increased H3K27me3 in Ezh2 Y641F/+ samples. These clusters were present in both B cells and melanoma cells with substantial overlap of dynamic regions (Supplementary Fig. 12b,c) . The finding of a large number of loci with dense H3K27me3 in Ezh2 +/+ samples that is lost in Ezh2 Y641F/+ B cells or melanoma was unexpected given the presumed hypermorphic activity of the mutant enzyme; yet such loci npg were even more obvious using a 'peak calling' algorithm (MACS 47 ), which assigns statistical significance to each dynamic peak. A 'volcano plot' of the log-transformed fold change of H3K27me3 peak signal versus log-transformed P value demonstrated that the peaks with the most highly significant change between Ezh2 +/+ and Ezh2 Y641F/+ samples were those that decreased 2-to 4-fold in Ezh2 Y641F/+ cells. Similarly to that seen in the PCA, there was a significant restoration of the WT peak pattern in Ezh2 Y641F/+ melanoma cells after JQEZ5 treatment ( Fig. 5b and Supplementary Fig. 12a) . We considered the possibility that this apparent decrease in peaks in Ezh2 Y641F/+ cells reflected an artifact of normalization, as a relative increase in genomewide H3K27me3 could dilute the intensity of the highest peaks seen in Ezh2 +/+ cells. However, we discounted this possibility for two reasons. Firstly, the fold decrease of H3K27me3 at certain loci (Fig. 5b) greatly exceeded the global increase in H3K27me3 by western analysis (Fig. 1b,i) , suggesting that dilution alone was an improbable cause. Secondly, the observed changes in peak height correlated with RNA expression at specific loci, for example, the marked increase in HoxC expression in Ezh2 Y641F/+ B cells correlated with H3K27me3 loss at this locus (Fig. 5c) , whereas Igf1 repression in Ezh2 Y641F/+ melanoma cells lines occurred in the setting of greatly increased H3K27me3 at this locus (Fig. 5c) . These observations suggest that the expression of mutant Ezh2 causes a global redistribution of H3K27me3, from highly focal peaks apparent in the Ezh2 +/+ samples to a greater number of broader, less focal peaks in the Ezh2 Y641F/+ samples, with attendant changes in gene expression.
We analyzed the effects of Ezh2 Y641F expression on the distribution of H3K27me3 at promoter regions, TSS and gene bodies. Toward that end, we rank-ordered transcripts by level of expression in Ezh2 +/+ samples and averaged the normalized H3K27me3 intensity ± 5 kb around the TSS for the top and bottom quartiles of expression ( Fig. 5d) . Consistent with previous work 48 , this analysis showed increased H3K27me3 flanking the TSS of genes with the lowest expression (black), with an obvious 'spike' of H3K27me3 immediately 3′ to the TSS. Expression of Ezh2 Y641F led to a relative decrease in H3K27me3 in the least transcribed genes, with little effect on H3K27me3 at transcripts in the highest quartile of expression. This observation suggests that the increased expression of some transcripts in Ezh2 Y641F -mutant cells (Supplementary Tables 1 and 2) results from a paradoxical loss of H3K27me3 around the TSSs of certain PRC2-repressed genes. (Mikkelsen) MCV6 HCP with H3K27me3   Igf1r  Epcam  Fos  Plin3  Cep250  Tmem38b  Cd9  Cd3g  Cd3d  Slc16a5  Cd28  Tns3  Prdm1  Rab3d  Mmp9  Itk  S100a8  Ltf  S100a9  Tmem176b  Tmem176a Cryba4 npg We next analyzed mean normalized H3K27me3 signal around the TSSs (±5 kb) of genes that showed a significant change in expression between Ezh2 +/+ and Ezh2 Y641F/+ cells (Supplementary Tables 1 and 2) . Genes that were upregulated in the presence of Ezh2 Y641F in both B cells and melanoma cell lines showed decreased H3K27me3 signals around the TSS, particularly immediately 3′ to the TSS (Fig. 5e,  left) . In contrast, genes that were downregulated in the presence of Ezh2 Y641F showed increased H3K27me3 signals, which started (on average) >2 kb downstream of TSSs (Fig. 5e, right) . These results are consistent with a prior report suggesting that H3K27me3 marks in the gene body are strongly repressive, whereas H3K27me3 marks in promoters are also in actively transcribed genes 48 . To further consider this possibility, we analyzed the presence of H3K27me3 along the gene body (from the TSS to the transcription termination site (TTS)) of transcripts that were differentially expressed between Ezh2 +/+ and Ezh2 Y641F/+ samples (Fig. 5f) . In contrast to the effects of Ezh2 mutations around the TSS, we observed a modest effect of Ezh2 Y641F on upregulated genes (P = 0.07) but a marked increase (P = 1.7 × 10 −15 ) of H3K27me3 signals in the gene bodies of downregulated genes (Fig. 5f) .
Finally, we analyzed the effect of the Ezh2 Y641F mutation on the entire genome, focusing on melanoma cell lines. To this end, we identified broad H3K27me3 domains in Ezh2 +/+ cells across the genome, and then compared the mean, normalized H3K27me3 signal 10 kb upstream and downstream of these domains in Ezh2 +/+ versus Ezh2 Y641F/+ samples. Consistent with our peak-calling analysis (Fig. 5b) , we observed a dramatic decrease in H3K27me3 signals in Ezh2 Y641F/+ samples, which was mostly restored after treatment with JQEZ5. Notably, however, we observed an increase in H3K27me3 signals that extended for more than 10 kb both 5′ and 3′ to these domains in Ezh2 Y641F/+ samples (Fig. 5g) . In aggregate, these results demonstrate that the Ezh2 Y641F mutant enzyme causes a global redistribution of H3K27me3 away from focal peaks (for example, near the TSS) across broad regions including gene bodies and intergenic regions.
DISCUSSION
Consistent with prior work 21 , we show that, under physiological conditions, global H3K27me3 levels are elevated in cells expressing Ezh2 Y641F , consistent with a model of increased enzymatic activity. However, using H3K27me3 ChIP-seq analysis, we provide evidence that the Tyr641Phe mutation does not monotonically increase H3K27me3, but rather redistributes the H3K27me3 mark across the genome, with complex effects on transcription. Through integrated analysis of ChIP-seq and RNA-seq, we observe loci in Ezh2 Y641F samples that show reduced H3K27me3 and increased gene expression, and vice versa. In particular, we note that the effects are not uniform with regard to genomic regions-the mutation seems to favor H3K27me3 over large regions (at gene bodies and intergenic regions) at the expense of focal peaks near the TSS. Although the mechanistic basis for this preference in unclear, the recent solution of the crystal structure of the yeast (Chaetomium thermophilum) PRC2 complex provides tantalizing clues 49 . In that study, the authors suggest that WT EZH2 is allosterically activated after EED binds H3K27me3, through reorganization of the complex that alters the lysine substrate channel of the enzyme in a manner similar to that by the Ala682 SET-domainencoding mutation 50 . This structure suggests that the yeast amino acid (Tyr826) homologous to Tyr646 also participates in the formation of this substrate channel, providing the possibility that this mutation npg reduces the need for H3K27me3-bound EED stimulation of the enzymatic complex, thereby creating a more promiscuous complex. Such a complex is expected to increase H3K27me3 at most nucleosomes. If some cofactor (such as SAM) for trimethylation were limiting, however, then such a complex might also show reduced H3K27me3 at focal peaks that perhaps more strongly require the stimulatory effects of the H3K27me3-EED interaction in cells expressing the WT complex. Regardless of the precise mechanistic details, however, the observations that Ezh2 Y641F expression decreases H3K27me3 at many loci ( Fig. 5b-g and Supplementary Fig. 12) , and that this effect is largely reversed by treatment with an EZH2 inhibitor (Fig. 5b,g and Supplementary Fig. 12a) , are not consistent with the notion that this is a strictly hypermorphic allele. Rather, we believe the allele should more properly be considered neomorphic, perhaps resulting from reduced requirements for H3K27me3-mediated autoactivation. Therapeutically, these results have direct implications for human cancers harboring mutations in the region encoding the Ezh2 SET domain. The overlap of gene expression signatures of Ezh2 activation and Myc repression in B lineage cancers ( Fig. 4b ) and the lack of cooperation between Myc overexpression and Ezh2 mutations in lymphomagenesis ( Fig. 1e) suggests the intriguing possibility that EZH2 mediates some of the transforming effects of Myc in lymphoma. Just as recent reports suggesting that mutations in BRCA1-associated protein 1 (BAP1) 51 , AT-rich interaction domain 1A (ARID1A) 52 and SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1 (SMARCB1) 53 predict sensitivity to EZH2 inhibitors, this finding suggests a rationale for testing EZH2 inhibitors in B cell neoplasms that are characterized by strong Myc activation. Additionally, we report a newly developed, potent pharmacologic EZH2 inhibitor, JQEZ5, with excellent in vitro and in vivo properties and that demonstrates marked in vivo antitumor activity in a faithful model of Ezh2-mutant cancer ( Fig. 3 and Supplementary  Fig. 6 ). Finally, the discovery of the exquisite and specific cooperation between activating genetic events of EZH2 and BRAF, but not NRAS ( Fig. 2 and Supplementary Fig. 5 ), predicts synergistic activity of combined therapy with RAF inhibitors (such as dabrafenib or vemurafenib) and EZH2 inhibitors in this heretofore unappreciated melanoma subtype that represents 3-9% of all individuals with melanoma.
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